Fluoxetine Induces Gastric Muscle Contraction

Published Online: Sunday, May 1, 2005

Selective serotonin reuptake inhibitors (SSRIs) have been used to treat a variety of neuropsychiatric disorders (depression, obsessive-compulsive disorder, panic disorder, bulimia nervosa). The majority (95%) of the body's serotonin is localized to the gut; thus, it is not surprising that SSRIs are associated with numerous gastrointestinal (GI)-related adverse effects. Despite the wide use of SSRIs, their effects on GI function, specifically GI motility, are ill defined.

The results from in vitro studies of fluoxetine on gastric muscle contractility were reported in Neurogastroenterology and Motility (February 2005). The contractile response of guinea pig stomach muscle strips was dose-dependent, and fundus muscle exhibited a stronger response than antral or pyloric circular muscle. Several serotonin receptor antagonists (atropine, tetrodotoxin, phentolamine, and GR113808, a selective serotonin [5-hydroxytryptamine] type 4 receptor partial agonist) were able to reduce the contractile response to fluoxetine. Atropine had the most dramatic effect, reducing the contractile response by 83% and 73% in the fundus and antral muscle, respectively. Based on the concentrations used in this study, the authors suggest that the serum concentration of fluoxetine in patients treated for psychiatric conditions may be sufficient to trigger adverse GI effects.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues